/ASBP
ASBP Stock - Aspire Biopharma Holdings, Inc.
Healthcare|BiotechnologyNASDAQ
$0.10-2.69%
$0.00 (-2.69%) • Dec 19
52
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.85
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.11
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ASBP
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.10 – $0.10
TARGET (TP)$0.11
STOP LOSS$0.09
RISK/REWARD1:1.6
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.87
52W High$15.80
52W Low$0.07
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Revenue | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A |
| Operating Income | $-3,088,671 | $-358,590 | $-596,491 |
| Net Income | $-12,537,472 | $-359,071 | $-597,117 |
| Net Margin | N/A | N/A | N/A |
| EPS | $-0.26 | $-0.01 | $-0.01 |
Company Overview
Aspire Biopharma Holdings, Inc. is a biotechnology company specializing in advanced diagnostic solutions and molecular testing. The company focuses on developing high-precision assays for disease detection, leveraging cutting-edge research in genetics and biochemistry to support healthcare and life sciences industries.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
ASBPBeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-0.04
Q4 2025
EPS Surprise History
Q2 25
No data
Q3 25
No data
Q4 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 14, 2025 | — | $-0.04 | — | — |
Q3 2025 | Aug 13, 2025 | — | $-0.04 | — | — |
Q2 2025 | May 14, 2025 | — | $-0.42 | — | — |
Latest News
Aspire Biopharma Granted Nasdaq Extension, Moves From The Nasdaq Global Select Market To The Nasdaq Capital Market On December 15, 2025
➖ NeutralBenzinga•Dec 12, 2025, 10:06 PM
Aspire Biopharma Filed For Offering Of Up To 41.5M Shares By Selling Shareholder
📉 NegativeBenzinga•Dec 3, 2025, 11:10 AM
Aspire Biopharma Submits Pre-IND Meeting Request And Briefing Package To FDA For Sublingual Aspirin Product In Suspected Acute Myocardial Infarction
📈 PositiveBenzinga•Dec 2, 2025, 02:02 PM
Aspire Biopharma Hldgs Q3 EPS $(0.04) Down From $(0.01) YoY, Sales $1.941K
📉 NegativeBenzinga•Nov 14, 2025, 02:31 PM
Aspire Biopharma Showcases Sublingual High-Dose Aspirin At CPHI Frankfurt
📈 PositiveBenzinga•Nov 6, 2025, 02:12 PM
Aspire Biopharma Files Omnibus Patent Application To Protect Advanced Sublingual Drug Delivery Technology Enhancing Bioavailability And Speed Of Onset
📈 PositiveBenzinga•Oct 6, 2025, 12:36 PM
Aspire Biopharma Holdings shares are trading higher after the company announced its Ezovion Electronic Medical Record platform has processed over $20 million in revenue.
📈 PositiveBenzinga•Oct 1, 2025, 04:51 PM
Aspire Biopharma Holdings shares are trading higher after the company announced a milestone roadmap targeting H2 2025 FDA Submission for Sublingual Asprin and 2026 milestones for Needle-Free Semaglutide and more-rapid ED medication.
📈 PositiveBenzinga•Oct 1, 2025, 04:40 PM
Aspire Biopharma Provides Pipeline Schedule
➖ NeutralBenzinga•Oct 1, 2025, 12:39 PM
Aspire Biopharma secures initial order for preworkout supplement, part of agreement with SupraNatural
📈 PositiveSeeking Alpha•Sep 16, 2025, 03:02 PM
Aspire Biopharma Expands BUZZ BOMB Pre-Workout Production With New SupraNaturals Manufacturing Agreement To Meet Growing Market Demand
📈 PositiveBenzinga•Sep 16, 2025, 12:37 PM
Aspire Biopharma Announces Final Results From Crossover Bioavailability Trial To Assess Safety, Tolerability, PK And PD Of Aspire's Investigational New Sublingual Aspirin Product Compared To Chewed Uncoated Aspirin Tablets In Healthy Adults
➖ NeutralBenzinga•Sep 3, 2025, 12:32 PM
Aspire Biopharma Holdings shares are trading higher after the company announced top-line data from its crossover bioavailability trial.
📈 PositiveBenzinga•Aug 18, 2025, 05:22 PM
Aspire Biopharma Announces Top-Line Data From Crossover Bioavailability Trial To Assess Safety, Tolerability, PK And PD Of Aspire's New Sublingual Aspirin Product Compared To Chewed Uncoated Aspirin Tablets In Healthy Adults
📈 PositiveBenzinga•Aug 18, 2025, 12:33 PM
Frequently Asked Questions about ASBP
What is ASBP's current stock price?
Aspire Biopharma Holdings, Inc. (ASBP) is currently trading at $0.10 per share. The stock has moved -2.69% today.
What is the analyst price target for ASBP?
No analyst price targets are currently available for this stock.
What sector is Aspire Biopharma Holdings, Inc. in?
Aspire Biopharma Holdings, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ASBP's market cap?
Aspire Biopharma Holdings, Inc. has a market capitalization of $0.00 billion, making it a small-cap company.
Does ASBP pay dividends?
No, Aspire Biopharma Holdings, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorADTX
Aditxt, Inc.
$1.17
Mkt Cap: $0.0B
BCTX
BriaCell Therapeutics Corp.
$8.95
Mkt Cap: $0.0B
CRIS
Curis, Inc.
$1.07
Mkt Cap: $0.0B
CTXR
Citius Pharmaceuticals, Inc.
$1.07
Mkt Cap: $0.0B
DARE
Daré Bioscience, Inc.
$2.09
Mkt Cap: $0.0B
ENTO
Entero Therapeutics, Inc.
$1.98
Mkt Cap: $0.0B
HOTH
Hoth Therapeutics, Inc.
$1.09
Mkt Cap: $0.0B
LPTX
Leap Therapeutics, Inc.
$1.09
Mkt Cap: $0.0B
PALI
Palisade Bio, Inc.
$1.83
Mkt Cap: $0.3B
PCSA
Processa Pharmaceuticals, Inc.
$3.78
Mkt Cap: $0.0B
Explore stocks similar to ASBP for comparison